TW202340190A - 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制劑及其用途 - Google Patents

外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制劑及其用途 Download PDF

Info

Publication number
TW202340190A
TW202340190A TW112102960A TW112102960A TW202340190A TW 202340190 A TW202340190 A TW 202340190A TW 112102960 A TW112102960 A TW 112102960A TW 112102960 A TW112102960 A TW 112102960A TW 202340190 A TW202340190 A TW 202340190A
Authority
TW
Taiwan
Prior art keywords
compound
alkyl
pharmaceutically acceptable
acceptable salt
cycloalkyl
Prior art date
Application number
TW112102960A
Other languages
English (en)
Chinese (zh)
Inventor
程鑫
劉穎濤
秦濼恒
任峰
余華星
Original Assignee
香港商英矽智能科技知識產權有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 香港商英矽智能科技知識產權有限公司 filed Critical 香港商英矽智能科技知識產權有限公司
Publication of TW202340190A publication Critical patent/TW202340190A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW112102960A 2022-01-28 2023-01-30 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制劑及其用途 TW202340190A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2022074739 2022-01-28
WOPCT/CN2022/074739 2022-01-28
CN2022140318 2022-12-20
WOPCT/CN2022/140318 2022-12-20

Publications (1)

Publication Number Publication Date
TW202340190A true TW202340190A (zh) 2023-10-16

Family

ID=87470622

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112102960A TW202340190A (zh) 2022-01-28 2023-01-30 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制劑及其用途

Country Status (12)

Country Link
US (1) US20250101019A1 (https=)
EP (1) EP4469456A4 (https=)
JP (1) JP2025502943A (https=)
KR (1) KR20240142481A (https=)
CN (1) CN118871439A (https=)
AR (1) AR128383A1 (https=)
AU (1) AU2023213905A1 (https=)
CA (1) CA3247162A1 (https=)
IL (1) IL313821A (https=)
MX (1) MX2024009216A (https=)
TW (1) TW202340190A (https=)
WO (1) WO2023143520A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024074128A1 (en) * 2022-10-08 2024-04-11 Insilico Medicine Ip Limited Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
CN121793967A (zh) * 2023-07-06 2026-04-03 英矽智能科技知识产权有限公司 外切核苷酸焦磷酸酶/磷酸二酯酶1 (enpp1)抑制剂组合及其用途
WO2025026383A1 (en) * 2023-08-02 2025-02-06 Insilico Medicine Ip Limited Crytsalline forms of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
WO2025026377A1 (en) * 2023-08-02 2025-02-06 Insilico Medicine Ip Limited Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE912874A1 (en) * 1990-08-15 1992-02-26 British Bio Technology Compounds
GB9200209D0 (en) * 1992-01-07 1992-02-26 British Bio Technology Compounds
US6489338B2 (en) * 2000-06-13 2002-12-03 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents
KR101142363B1 (ko) * 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
EP2099796B1 (en) * 2006-11-30 2011-06-01 Genentech, Inc. Aza-indolyl compounds and methods of use
WO2015038417A1 (en) * 2013-09-10 2015-03-19 Asana Biosciences, Llc Compounds for regulating fak and/or src pathways
CN111615388B (zh) * 2017-07-27 2023-11-14 斯汀格瑞治疗股份有限公司 癌症免疫治疗剂
CN111732584B (zh) * 2019-03-25 2024-02-27 复旦大学 二芳基取代稠杂环类化合物及其制备方法和在制药中的用途
JP7598875B2 (ja) * 2019-04-12 2024-12-12 リボサイエンス リミティド ライアビリティ カンパニー エクトヌクレオチドピロホスファターゼホスホジエステラーゼ1阻害剤としての二環式ヘテロアリール誘導体
CN115151253B (zh) * 2019-09-23 2025-04-15 南京征祥医药有限公司 磷酸二酯酶抑制剂及用途
CA3291973A1 (en) * 2021-01-29 2026-03-02 Txinno Bioscience Inc. Benzotriazole Derivative Having Inhibitory Activity Against Ectonucleotide Pyrophosphatase-Phosphodiesterase, and Use Thereof

Also Published As

Publication number Publication date
IL313821A (en) 2024-08-01
US20250101019A1 (en) 2025-03-27
EP4469456A4 (en) 2025-12-31
CN118871439A (zh) 2024-10-29
KR20240142481A (ko) 2024-09-30
AU2023213905A1 (en) 2024-07-11
CA3247162A1 (en) 2023-08-03
MX2024009216A (es) 2024-08-06
WO2023143520A1 (en) 2023-08-03
AR128383A1 (es) 2024-04-24
EP4469456A1 (en) 2024-12-04
JP2025502943A (ja) 2025-01-30

Similar Documents

Publication Publication Date Title
TW202340190A (zh) 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制劑及其用途
EP4532486A1 (en) Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof
KR101880280B1 (ko) 키나제 억제제로서의 퀴놀린 및 퀴녹살린 유도체
JP7337395B2 (ja) Cdk4およびcdk6阻害剤としての2h-インダゾール誘導体およびその治療上の使用
TWI870770B (zh) Parp1抑制劑及其用途
CN110092787B (zh) 一种化合物或其药用盐或组合物的制备及应用
TW202327600A (zh) 甲硫胺酸腺苷轉移酶2a(mat2a)抑制劑及其用途
RU2741000C2 (ru) Производное 1,4-дизамещенного имидазола
TW202334158A (zh) 含脯胺醯羥化酶結構域之蛋白質(phd)抑制劑及其用途
WO2024074128A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
CA3179671A1 (en) Kinase inhibitors and uses thereof
CN108601773B (zh) 作为pi3k/mtor抑制剂的稠合喹啉化合物
WO2019136093A1 (en) Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
CN114599655A (zh) 咪唑烷酮类化合物及其制备方法与应用
WO2025026377A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
EA052691B1 (ru) Ингибиторы эктонуклеотидпирофосфатазы-фосфодиэстеразы 1 (enpp1) и их применение
HK40116343A (zh) 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制剂及其用途
AU2010242394B2 (en) Purine derivative and antitumor agent using same
CN119874676A (zh) 一种pi3k抑制剂及其制备方法和用途
HK40076191A (en) Imidazolidinone compound, preparation method therefor and use thereof